Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure
- PMID: 17410445
- DOI: 10.1007/s10620-006-9726-8
Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure
Abstract
In a prospective therapeutic trial, features of the hepatitis C quasispecies were investigated as possible markers of therapeutic response. Individuals chronically infected with hepatitis C genotype 1 received antiviral therapy consisting of alpha-interferon plus ribavirin. The study targeted the most rapidly evolving segment of the viral genome, hypervariable region 1 within the envelope-2 gene. Among individuals failing to clear virus in response to therapy, significant differences were observed between quasispecies of African-American and Caucasian subjects. While distance measures for synonymous substitutions were similar between racial subgroups, measures of distance at the amino acid level (nonsynonymous substitutions) varied significantly. Taken together, the observed patterns of variability corresponded to reduced host selection pressure against hypervariable region 1 in African-American nonresponders. Reduced selection pressure was present at baseline and persisted through treatment and follow-up, suggesting population stratification of host factors that influence selection pressure on hepatitis C virus.
Similar articles
-
Identification of a hepatitis C virus mutant lacking the hypervariable region 1 in a chronically infected patient non-responding to PEG-interferon-alpha/ribavirin therapy.Eur J Clin Microbiol Infect Dis. 2009 Feb;28(2):211-3. doi: 10.1007/s10096-008-0608-1. Epub 2008 Aug 28. Eur J Clin Microbiol Infect Dis. 2009. PMID: 18752008 No abstract available.
-
Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection.J Clin Gastroenterol. 2010 Feb;44(2):140-5. doi: 10.1097/MCG.0b013e3181ba9992. J Clin Gastroenterol. 2010. PMID: 19826275
-
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.Gastroenterology. 2006 Aug;131(2):470-7. doi: 10.1053/j.gastro.2006.06.008. Gastroenterology. 2006. PMID: 16890601 Clinical Trial.
-
Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.J Gastroenterol. 2009;44(10):1009-15. doi: 10.1007/s00535-009-0126-7. J Gastroenterol. 2009. PMID: 19756352 Review.
-
The evolving treatment of chronic hepatitis C: where we stand a decade out.Cleve Clin J Med. 2004 May;71 Suppl 3:S3-7. doi: 10.3949/ccjm.71.suppl_3.s3. Cleve Clin J Med. 2004. PMID: 15468610 Review.
Cited by
-
Ethnic variations in chronic liver diseases.Dig Dis Sci. 2008 May;53(5):1339-44. doi: 10.1007/s10620-007-9992-0. Epub 2007 Oct 13. Dig Dis Sci. 2008. PMID: 17934812 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases